SADA-5 (Strategy of Assessment for Drug Appropriateness) Criteria as a Powerful Tool for Detecting Potentially Inappropriate Medications with Using Another Explicit Criteria; a Randomized Control Trial

SADA-5 (Strategy of Assessment for Drug Appropriateness) Criteria as a Powerful Tool for Detecting Potentially Inappropriate Medications with Using Another Explicit Criteria; a Randomized Control Trial - SADA-5 trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024250

Enrollment

154

Registered

2016-10-11

Start date

2016-10-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients who are just admitted in Kameda rehabilitation hospital and have one or more prescription drugs.

Interventions

In an intervention group, the evaluators evaluate the appropriateness of drugs using Screening Tool for Older Persons&#39

Appropriate Prescriptions in Japanese (STOPP-J) and SADA (Strategy of Assessment for Drug Appropriateness)-5 criteria. Two senior residents in the Department of General Internal Medicine of Kameda Med

Appropriate Prescriptions in Japanese (STOPP-J). One senior resident in the Department of General Internal Medicine of Kameda Medical Center is the protocol evaluator.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patient who are 65 years old and older, admitted to Kameda Rehabilitation Hospital under the care of rehabilitation physicians, and have one or more oral prescription drugs.

Exclusion criteria

Exclusion criteria: 1) unwillingness of the patient to participate in the study. 2) a patient who have no oral prescription drug. 3) a patient under 65 years old.

Design outcomes

Primary

Measure	Time frame
The number of potentially inappropriate medications (PIMs) whichI is evaluated in each criteria.	—

Secondary

Measure	Time frame
1) The appropriateness of prescribing as measured by the Medicine Appropriateness Index 2) The number of all prescribing drugs at discharge 3) Reduced cost by deprescribing drugs 4) Adverse events by deprescribing drugs	—

Countries

Japan

Contacts

Public ContactSada Ryuichi

Kameda Medical Center Department of General Internal Medicine

sada.ryuichi@kameda.jp81-4-7092-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026